CLINICAL EFFICACY OF ZOLEDRONIC ACID IN THE TREATMENT OF SENILE OSTEOPOROSIS
Main Article Content
Keywords
Clinical efficacy, Zoledronic Acid, Treatment, Senile Osteoporosis
Abstract
Background: Patients with osteoporosis are given medication treatments in clinics to boost their bone mineral density and lower their risk of fracture. In the past, senile osteoporosis was often treated with oral calcium D supplementation, which can have therapeutic effects. However, in practical application, the overall effective rate is generally poor
Objective: this study was carried out to explore the Clinical efficacy of Zoledronic Acid in the treatment of Senile Osteoporosis
Materials and methods: This study was conducted at the Orthopaedic department MTI mardan medical complex from May 2022 December 2023. A total of 165 participants diagnosed with osteoporosis were enrolled. All patients diagnosed with osteoporosis and had the ability to endure the testing medication were included in this study and those had fracture other than osteoporosis and had organ failure like liver digestive system disorders thyroid abnormalities or tumors were excluded. Conventional therapy was administered to the control group, and zoledronic acid was added to the treatment regimen for the observation group. The two groups' bone mineral density, level of discomfort, treatment outcome, and adverse events were compared. All the data was analyzed by using SPSS version 23.
Results: The observation group's overall effective rate was 96.67%, which was greater than the control group's 80.00% (P<0.05). After six months of therapy, the bone density of the two groups reach to satisfaction in the lumbar vertebrae, femoral neck, and Ward' region, with the observation group showing a greater rise than the control group (P<0.05). After six months of therapy, the observation group's pain level was lower than the control groups, and the difference was statistically significant (P<0.05). Between the two groups, there was not a significant difference in the incidence of adverse responses (P>0.05).
Conclusion: In addition to being highly safe while treating senile osteoporosis, zoledronic acid is beneficial in reducing the severity of bone pain, promoting the growth of bone mass, and relieving clinical symptoms.
References
2. Hammoudeh M, Al-Khayarin M, Zirie M, Bener A. Bone density measured by dual energy X-ray absorptiometry in Qatari women. Maturitas2005; 52:319-27.
3. World health organization (WHO).Guidelines for preclinical evaluation and clinical trials in osteoporosis. World Health Organization. Geneva 1998.
4. National Osteoporosis Foundation (NOF). Clinician? Guide to Prevention and Treatment of Osteoporosis 2009.
5. Marx RE.Oral Bisphosphonate-Induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention and Treatment.J Oral MaxillofacSurg2007; 65:2397-410.
6. Tammy McClish MED. Fundamentals of bone densitometry.2009; pp: 1-79 Follin SL, Black JN, McDermott MT.Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture. Pharmacother J Hum Pharmacol Drug Ther. 2012; 23(2):190-198.
7. Li Q, Chen DK. Effect of diphosphonate in the treatment of Th17 and Treg cytokines secretion imbalance induced by osteoporosis.Chin J Gerontol. 2018; 38(6):1418-1419.
8. Guo BL, Li FQ. The safety observation of zoledronic acid in the treatment of senile osteoporosis.Chin J Osteoporos. 2014; 20(7):820-823.
9. LaFleur J, DuVall SL, Willson T, Ginter T, Patterson O, Cheng Y, et al. Analysis of osteoporosis treatment patterns with bisphosphonates and outcomes among postmenopausal veterans. Bone. 2015; 78:174-185.
10. 15. Diab DL, Watts NB. Bisphosphonates in the treatment of osteoporosis. Endocrin Metab Clin. 2012;41(3):487-506.
11. Lozano MJF, Sanchezfidalgo S. Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates. Eur J Hosp Pharm. 2019; 26(1):4-9.
12. Recknor C. Zoledronic acid for prevention and treatment of osteoporosis. Expert Opin Pharmacother. 2011; 12(5):807-815.
13. Sun XG, Zhu HY. The analysis of the therapeutic efficacy of the postmenopausal osteoporosis women with intravenous zoledronic acid treatment. Clin Res and Pract. 2016; 1(17):35-36.
14. Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, et al. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res. 2009; 24(9):1544-1551.
15. Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med. 2005; 165(3):346-347.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Tariq Ahmad
Assistant Professor orthopaedic Surgery MTI Mardan Medical Complex, Mardan
Suresh Kumar
Consultant Orthopaedic Surgeon Ruth K.M Pfau Civil Hospital, Karachi
Allah Nawaz Abbasi
Associate Professor Department of Orthopaedic, PUMHS, Nawab Shah
Nazeer Ahmed Memon
Senior Registrar, Medicine Al-Tibri Medical College and Hospital Isra University Karachi Campus
Saboohi Irfan
Senior Registrar, Medicine Al-Tibri Medical College and Hospital Isra University Karachi Campu